MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer

Y Lu1,2, T Qin3,2, J Li3,2

  • 1Teaching Laboratory of Morphology, Dalian Medical University, Dalian, China.

Cancer Gene Therapy
|July 29, 2017
PubMed

Insights

MicroRNA-140-5p acts as a tumor suppressor in breast cancer. This study shows miR-140-5p inhibits cancer invasion and angiogenesis by targeting VEGF-A, offering a potential new therapy.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) regulate gene expression and are implicated in cancer progression, including metastasis and angiogenesis.
  • miR-140-5p has been identified as a tumor suppressor in various human cancers, but its specific role in breast cancer invasion and angiogenesis requires further elucidation.

Purpose of the Study:

  • To investigate the molecular mechanism by which miR-140-5p affects breast cancer invasion and angiogenesis.
  • To identify the direct target of miR-140-5p involved in these processes.

Main Methods:

  • Quantitative analysis of miR-140-5p expression in breast cancer tissues.
  • In vitro assays (Transwell invasion, tube formation) using miR-140-5p mimics in breast cancer cell lines (MCF-7, MDA-MB-231).
  • In vivo validation using immunohistochemistry and Western blot to assess invasion and angiogenesis markers (VEGF-A, CD31, MMP-9), and dual-luciferase reporter assays to confirm target interaction.

Main Results:

  • Decreased miR-140-5p mRNA levels were observed in metastatic breast cancer tissues compared to non-metastatic ones.
  • Overexpression of miR-140-5p significantly inhibited breast cancer cell invasion and angiogenesis in vitro.
  • VEGF-A was identified and validated as a direct target of miR-140-5p, with its expression reduced upon miR-140-5p mimic transfection.

Conclusions:

  • miR-140-5p suppresses breast cancer invasion and angiogenesis by directly targeting VEGF-A.
  • The findings reveal a novel molecular mechanism for miR-140-5p in breast cancer.
  • This study provides a strong foundation for developing novel microRNA-based therapeutic strategies for breast cancer treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K